ABBOTT LABORATORIES — Director's Dealing 2020

Jan 30, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2020-01-28

Reporting Person: YOOR BRIAN B (Executive Vice President & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-28	Common shares without par value	M	41229	$47	Acquired	155610	Direct
2020-01-28	Common shares without par value	M	81709	$48.90	Acquired	237319	Direct
2020-01-28	Common shares without par value	M	213470	$38.40	Acquired	450789	Direct
2020-01-28	Common shares without par value	M	91121	$44.40	Acquired	541910	Direct
2020-01-28	Common shares without par value	M	82321	$59.94	Acquired	624231	Direct
2020-01-28	Common shares without par value	S	509850	$89.7268	Disposed	114381	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-28	Option (right to buy)	$47.00	M	41229	Disposed	2025-02-19	Common shares (41229)	Direct
2020-01-28	Option (right to buy)	$48.90	M	81709	Disposed	2025-05-31	Common shares (81709)	Direct
2020-01-28	Option (right to buy)	$38.40	M	213470	Disposed	2026-02-18	Common shares (213470)	Direct
2020-01-28	Option (right to buy)	$44.40	M	91121	Disposed	2027-02-16	Common shares (91121)	Direct
2020-01-28	Option (right to buy)	$59.94	M	82321	Disposed	2028-02-15	Common shares (82321)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	2239	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.57 to $89.87, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of January 28, 2020.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.